In summary, we show here that an SSTR2 antagonist can improve the glucagon counterregulatory response to insulin-induced hypoglycemia and prevent, or at least delay, the onset of hypoglycemia by up to −40 min in a rat model of T2D. Here, INS is linked to type 2 diabetes mellitus.